111
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Fixed Ratio versus Lower Limit of Normality for Diagnosing COPD in Primary Care: Long-Term Follow-Up of EGARPOC Study

ORCID Icon, ORCID Icon, ORCID Icon, , , ORCID Icon & show all
Pages 1403-1413 | Published online: 18 Jun 2020

References

  • RothGA, AbateD, Hassen AbateK, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–1788. doi:10.1016/S0140-6736(18)32203-730496103
  • AlmagroP, SorianoJB. Underdiagnosis in COPD: a battle worth fighting. Lancet Respir Med. 2017;5(5):367–368. doi:10.1016/S2213-2600(17)30133-928389226
  • Global Initiative for Chronic Obstructive Lung Disease - 2019 Available at: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed 1012, 2019..
  • Guirguis-BlakeJM, SengerCA, WebberEM, et al. Screening for chronic obstructive pulmonary disease. JAMA. 2016;315(13):1378. doi:10.1001/jama.2016.265427046366
  • KaplanA, ThomasM. Screening for COPD: the gap between logic and evidence. Eur Respir Rev. 2017;26(143):160113. doi:10.1183/16000617.0113-201628298389
  • QuanjerPH, BrazzaleDJ, BorosPW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42(4):1046–1054. doi:10.1183/09031936.0019551223520323
  • TurkeshiE, VaesB, AndreevaE, et al. Airflow limitation by the Global Lungs Initiative equations in a cohort of very old adults. Eur Respir J. 2015;46(1):123–132. doi:10.1183/09031936.0021721425882799
  • LuotoJA, ElmståhlS, WollmerP, et al. Incidence of airflow limitation in subjects 65-100 years of age. Eur Respir J. 2016;47(2):461–472. doi:10.1183/13993003.00635-201526677939
  • WoodruffPG, BarrRG, BleeckerE, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med. 2016;374(19):1811–1821. doi:10.1056/NEJMoa150597127168432
  • ReganEA, LynchDA, Curran-EverettD, et al. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern Med. 2015;175(9):1539–1549. doi:10.1001/jamainternmed.2015.273526098755
  • WheltonPK, CareyRM, AronowWS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;(17):138. doi:10.1161/CIR.0000000000000596
  • WarrenB, PankowJS, MatsushitaK, et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2017;5(1):34–42. doi:10.1016/S2213-8587(16)30321-727863979
  • GrundySM, StoneNJ, BaileyAL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350. doi:10.1016/j.jacc.2018.11.00330423393
  • BressAP, ColantonioLD, CooperRS, et al. Potential cardiovascular disease events prevented with adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. Circulation. 2019;139(1):24–36. doi:10.1161/CIRCULATIONAHA.118.03564030586736
  • LlordésM, JaénA, AlmagroP, et al. Prevalence, risk factors and diagnostic accuracy of COPD among smokers in primary care. COPD J Chronic Obstr Pulm Dis. 2015;12(4):404–412. doi:10.3109/15412555.2014.974736
  • CastellE, GaroleraD, VilellaA, et al. Adaptació al català de l’enquesta de malalties respiratories ATS-DLD-78. Validació preliminar. Ann Med. 1988;74(9):231–239.
  • MonsóE, RibasJ, CarreresA, et al. Diseño de un cuestionario ocupacional para ser utilizado en la práctica neumológica diaria. Ann Med. 1993;3:43–46.
  • GLI-2012 Desktop Software for Data Sets. Available from: http://www.lungfunction.org/tools/90-equations-and-tools/196-obtainsoftware.html. Accessed 1012, 2019.
  • BestallJC, PaulEA, GarrodR, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. doi:10.1136/thx.54.7.58110377201
  • Soler-CataluñaJJ, Martínez-GarcíaMÁ, SánchezLS, et al. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009;103(5):692–699. doi:10.1016/j.rmed.2008.12.00519131231
  • AlmagroP, SorianoJB, CabreraFJ, et al. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest. 2014;145(5):972–980. doi:10.1378/chest.13-132824077342
  • MiravitllesM, Soler-CataluñaJJ, CalleM, et al. Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Aten Primaria. 2012;44(7):425–437. doi:10.1016/j.aprim.2012.04.00522704760
  • CharlsonME, PompeiP, AlesKL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
  • AlmagroP, CabreraFJ, DiezJ, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en servicios de medicina interna (ESMI) study. Chest. 2012;142(5):1126–1133. doi:10.1378/chest.11-241323303399
  • MillerMR, HankinsonJ, BrusascoV, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.0003480516055882
  • RocaJ, SanchisJ, Agusti-VidalA, et al. Spirometric reference values from Mediterranean population. Bull Eur Physiopathol Respir. 1986;22(3):217–224.3730638
  • Von ElmE, AltmanDG, EggerM, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ. 2007;85(11):867–872. doi:10.2471/blt.07.04512018038077
  • VestboJ, EdwardsLD, ScanlonPD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192. doi:10.1056/NEJMoa110548221991892
  • LuotoJ, PihlsgårdM, WollmerP, et al. Relative and absolute lung function change in a general population aged 60-102 years. Eur Respir J. 2019;53(3):1701812. doi:10.1183/13993003.01812-201730578401
  • FriesJF. Aging, natural death, and the compression of morbidity. N Engl J Med. 1980;303(3):130–135. doi:10.1056/NEJM1980071730303047383070
  • RasmussenSH, Andersen-RanbergK, DahlJS, et al. Diagnosing heart failure in centenarians. J Geriatr Cardiol. 2019;16(1):1–11. doi:10.11909/j.issn.1671-5411.2019.01.00830800145
  • ItoK, BarnesPJ. COPD as a disease of accelerated lung aging. Chest. 2009;135(1):173–180. doi:10.1378/chest.08-141919136405
  • ArjomandiM, ZengS, BarjaktarevicI, et al. Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS. Eur Respir J. 2019;54:4. doi:10.1183/13993003.02214-2018
  • CelliBR, WedzichaJA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1257–1266. doi:10.1056/NEJMra190050031553837
  • YoungAL, BragmanFJS, RangelovB, et al. Disease progression modelling in chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. 2019. doi:10.1164/rccm.201908-1600OC
  • EschenbacherWL. Defining airflow obstruction. Chronic Obstr Pulm Dis. 2016;3(2):515–518. doi:10.15326/jcopdf.3.2.2015.016627239557
  • AgustíA, CelliB, FanerR. What does endotyping mean for treatment in chronic obstructive pulmonary disease? Lancet. 2017;390(10098):980–987. doi:10.1016/S0140-6736(17)32136-028872030
  • TorénK, AnderssonM, OlinAC, et al. Airflow limitation classified with the fixed ratio or the lower limit of normal and cause-specific mortality – a prospective study. Respir Med. 2018;144:36–41. doi:10.1016/j.rmed.2018.10.00130366582
  • OdeyemiYE, LewisO, NgwaJ, et al. Does low FEV1 in addition to fixed ratio and/or lower limit of normal of FEV1/FVC improve prediction of mortality in COPD?.The NHANES-III-linked-mortality Cohort. J Natl Med Assoc. 2019;111(1):94–100. doi:10.1016/j.jnma.2018.06.00630064691
  • OhDK, BaekS, LeeSW, et al. Comparison of the fixed ratio and the Z-score of FEV1/FVC in the elderly population: a long-term mortality analysis from the Third National Health and Nutritional Examination Survey. Int J Chron Obstruct Pulmon Dis. 2018;13:903–915. doi:10.2147/COPD.S14842129559774
  • BhattSP, BaltePP, SchwartzJE, et al. Discriminative accuracy of FEV1/FVC thresholds for COPD-related hospitalization and mortality. JAMA. 2019;321(24):2438–2447. doi:10.1001/jama.2019.723331237643
  • CalverleyPMA, MuellerA, FowlerA, et al. The effect of defining chronic obstructive pulmonary disease by the lower limit of normal of FEV1/FVC ratio in Tiotropium safety and performance in respimat participants. Ann Am Thorac Soc. 2018;15(2):200–208. doi:10.1513/AnnalsATS.201703-194OC28957643